# Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent

> **NCT01025479** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 829 (actual)

## Conditions studied

- Prostate Cancer
- Osteoporosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01025479
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 829 (ACTUAL)
- **Last updated:** 2010-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01025479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01025479, "Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01025479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*